Patent ID: 11932693
Assignee: GENMAB A/S
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC C

Claim 0:
1. An antibody or antigen-binding fragment thereof having the ability to bind to PD-1, wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain having a heavy chain constant region (CH) and a heavy chain variable region (VH) and a light chain having a light chain constant region (CL) and a light chain variable region (VL),
wherein the heavy chain constant region is a human IgG1 constant region that comprises phenylalanine at the position corresponding to position 234 in a human IgG1 heavy chain according to EU numbering, glutamate at the position corresponding to position 235 in a human IgG1 heavy chain according to EU numbering, and arginine at the position corresponding to position 236 in a human IgG1 heavy chain according to EU numbering, and
wherein (i) the heavy chain variable region (VH) comprises a HCDR1, HCDR2, and HCDR3 sequence, wherein the HCDR1, HCDR2 and HCDR3 sequences according to Kabat numbering comprise or have the sequence as set forth in SEQ ID NO: 12, SEQ ID NO: 11, and SEQ ID NO: 8, respectively, and
the light chain variable region (VL) comprises a LCDR1, LCDR2, and LCDR3 sequence, wherein the LCDR1, LCDR2 and LCDR3 sequences according to Kabat numbering comprise or have the sequence as set forth in SEQ ID NO: 17, SEQ ID NO: 15, and SEQ ID NO: 14, respectively; or
(ii) the heavy chain variable region (VH) comprises a HCDR1, HCDR2, and HCDR3 sequence, wherein the HCDR1, HCDR2 and HCDR3 sequences according to IMGT numbering comprise or have the sequence as set forth in SEQ ID NO: 13, SEQ ID NO: 10, and SEQ ID NO: 9, respectively, and
the light chain variable region (VL) comprises a LCDR1, LCDR2, and LCDR3 sequence, wherein the LCDR1, LCDR2 and LCDR3 sequences according to IMGT numbering comprise or have the sequence as set forth in SEQ ID NO: 16, QAS, and SEQ ID NO: 14, respectively.